Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L01XEOrphan Medicine

Cometriq(cabozantinib)

Thyroid Neoplasms

Marketing Authorisation Holder: Ipsen Pharma

EMA Authorisation: 21/03/2014

INN: cabozantinib

Indication

Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cometriq — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.